Marilena De Mariano
Overview
Explore the profile of Marilena De Mariano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cirmena G, Garuti A, De Mariano M, Coco S, Ferrando L, Isnaldi E, et al.
J Oncol
. 2020 May;
2020:8132507.
PMID: 32377196
In breast cancer patients undergoing neoadjuvant chemotherapy before surgery, there is an unmet need for noninvasive predictive biomarkers of response. The analysis of circulating tumor DNA (ctDNA) in particular has...
2.
Aveic S, Pantile M, Polo P, Sidarovich V, De Mariano M, Quattrone A, et al.
Cancer Cell Int
. 2018 May;
18:63.
PMID: 29713246
Background: A growing field of evidence suggests the involvement of oncogenic receptor tyrosine kinases (RTKs) in cell transformation. Deregulated activity of RTKs in tumors can determine disease progression and therapeutic...
3.
Sidarovich V, De Mariano M, Aveic S, Pancher M, Adami V, Gatto P, et al.
Mol Cancer Ther
. 2018 Apr;
17(7):1405-1415.
PMID: 29695637
Novel druggable targets have been discovered in neuroblastoma (NB), paving the way for more effective treatments. However, children with high-risk NB still show high mortality rates prompting for a search...
4.
Cirmena G, Franceschelli P, Isnaldi E, Ferrando L, De Mariano M, Ballestrero A, et al.
Cancer Lett
. 2018 Mar;
425:13-20.
PMID: 29596888
Oncogenic alteration of the cholesterol synthesis pathway is a recognized mechanism of metabolic adaptation. In the present review, we focus on squalene epoxidase (SE), one of the two rate-limiting enzymes...
5.
De Mariano M, Stigliani S, Moretti S, Parodi F, Croce M, Bernardi C, et al.
Oncotarget
. 2017 Sep;
8(34):56518-56532.
PMID: 28915608
The discovery of missense mutations of gene identified this receptor tyrosine kinase as a therapeutic target in neuroblastoma (NB). Moreover, a high level of ALK protein has been associated with...
6.
Lasorsa V, Formicola D, Pignataro P, Cimmino F, Calabrese F, Mora J, et al.
Oncotarget
. 2016 Mar;
7(16):21840-52.
PMID: 27009842
The spectrum of somatic mutation of the most aggressive forms of neuroblastoma is not completely determined. We sought to identify potential cancer drivers in clinically aggressive neuroblastoma.Whole exome sequencing was...
7.
De Mariano M, Gallesio R, Chierici M, Furlanello C, Conte M, Garaventa A, et al.
Oncotarget
. 2015 Aug;
6(28):26335-46.
PMID: 26309160
Although several genes have been associated to neuroblastoma (NB) predisposition and aggressiveness, further genes are likely involved in the overall risk of developing this pediatric cancer. We thus carried out...
8.
Mazzocco K, Defferrari R, Sementa A, Garaventa A, Longo L, De Mariano M, et al.
Pediatr Blood Cancer
. 2015 May;
62(10):1725-32.
PMID: 25925003
Background: Less than 5% of neuroblastomas (NB) occur in adolescents and young adults (AYA), in whom the disease has an indolent and fatal course. Procedure: We studied the genomic profile...
9.
Lambertz I, Kumps C, Claeys S, Lindner S, Beckers A, Janssens E, et al.
Clin Cancer Res
. 2015 Mar;
21(14):3327-39.
PMID: 25805801
Purpose: Activating ALK mutations are present in almost 10% of primary neuroblastomas and mark patients for treatment with small-molecule ALK inhibitors in clinical trials. However, recent studies have shown that...
10.
Romania P, Castellano A, Surace C, Citti A, De Ioris M, Sirleto P, et al.
PLoS One
. 2013 Nov;
8(10):e78481.
PMID: 24205241
Neuroblastoma (NB), the most common solid cancer in early childhood, usually occurs sporadically but also its familial occurance is known in 1-2% of NB patients. Germline mutations in the ALK...